Masarykuv onkologicky ustav | ClinicalTrials HQ

3 results · Page 1 of 1

Swipe the table sideways for more columns.

Trial	Conditions	Status	Phase	Updated	More info	NCT ID
Study of TDXd, Chemotherapy, Pembrolizumab, and Trastuzumab in First-Line Metastatic HER2-Positive Gastric or Gastroesophageal Junction Cancer	Digestive System Diseases, Digestive System Neoplasms, Neoplasms by Site, digestive system disorder, digestive system neoplasm, gastric cancer, gastric neoplasm, neoplasm, stomach disorder	Recruiting	Phase 3	2026-08-10		NCT06731478
Clinical Performance of Medical Device Software "Lipidica 1.0" for Processing Data Generated by Lipidomic Analysis in Pancreatic Cancer Screening	Chronic Disease, Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Digestive System Diseases, Digestive System Neoplasms, Disease Attributes, Neoplasms by Site, Pathologic Processes, Pathological Conditions, Signs and Symptoms, chronic pancreatitis, endocrine system disorder, hereditary disease, malignant endocrine neoplasm, malignant pancreatic neoplasm, neoplasm, pancreas disorder, pancreatic ductal adenocarcinoma, pancreatic neoplasm, pancreatitis	Recruiting	Not applicable	2026-04-27		NCT06549725
Lenvatinib/Everolimus or Lenvatinib/Pembrolizumab Versus Sunitinib Alone as Treatment of Advanced Renal Cell Carcinoma	Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Male Urogenital Diseases, Neoplasms by Histologic Type, Neoplasms by Site, Urogenital Diseases, Urogenital Neoplasms, adenocarcinoma, benign urinary system neoplasm, carcinoma, epithelial neoplasm, kidney cancer, kidney disorder, neoplasm, renal cell carcinoma, urinary system disorder	Active, not recruiting	Phase 3	2026-02-23		NCT02811861